Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.
Status:
Completed
Trial end date:
2021-07-02
Target enrollment:
Participant gender:
Summary
The aim is to determine the recommended phase 2 dose (RP2D) of binimetinib in combination
with pemetrexed and cisplatin, and to demonstrate that the combination is feasible and has
preliminary activity in previously untreated patients with advanced NSCLC and documented KRAS
mutations.